Effects of TCF7L2 polymorphisms on glucose values after a lifestyle intervention

American Journal of Clinical Nutrition

Volumn 90, Issue 6, 2009, Pages 1502-1508

  Bo, Simona ^a   Gambino, Roberto ^a   Ciccone, Giovannino ^b   Rosato, Rosalba ^b   Milanesio, Nadia ^a   Villois, Paola ^a   Pagano, Gianfranco ^a   Cassader, Maurizio ^a   Gentile, Luigi ^c   Durazzo, Marilena ^a   Cavallo Perin, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Hospital of Asti   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; EXERCISE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RELEASE; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OPEN STUDY; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 72749117166     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2009.28379     Document Type: Article

References (31)

1. Grant SFA, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323 (Pubitemid 43315754)
2. Weedon MN. The importance of TCF7L2. Diabet Med 2007;24:1062-1066
3. Smith U. TCF7L2 and type 2 diabetes-we WNT to know. Diabetologia 2007;50:5-7. (Pubitemid 46035845)
4. Florez JC, Jablonski KA, Bayley N, et al, for the Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355: 241-250
5. Wang J, Kuusisto J, Vänttinen M, et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes prevention study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 2007; 50:1192-1200 (Pubitemid 46701561)
6. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-2232
7. Reinehr T, Friedel S, Mueller TD, Toschke AM, Hebebrand J, Hinney A. Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention. Int J Obes (Lond) 2008;32: 1521-1524
8. Kallio P, Kolehmainen M, Laaksonen DE, et al. Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT Study. Am J Clin Nutr 2007;85:1417-1427 (Pubitemid 46740487)
9. Cauchi S, Choquet H, Gutiérrez-Anguilar R, et al. Effects of TCF7L2 polymorphisms on obesity in European populations. Obesity (Silver Spring) 2008;16:476-482 (Pubitemid 351271935)
10. Lindahl B, Nilsson T, Borch-Johnsen K, et al. A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: pronounced short-term impact but long-term adherence problems. Scand J Public Health 2009;37:434-442
11. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8: 1-182.
12. Bo S, Ciccone G, Baldi C, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med 2007;22:1695-1703 (Pubitemid 350160343)
13. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:391-397
14. Bo S, Gentile L, Ciccone G, et al. The metabolic syndrome and high C-reactive protein: prevalence and difference by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 2005;21: 515-524 (Pubitemid 41646011)
15. National Institutes of Health. The practical guide. Identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health, 2000. (NIH publication 00-4084.)
16. Bo S, Durazzo M, Guidi S, et al. Dietary magnesium and fiber intake, inflammatory and metabolic parameters in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006;84:1062-1069 (Pubitemid 44730376)
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(suppl 1): S5-20.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-441
20. Tong Y, Lin Y, Zhang Y, et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large human genome epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009;10:15.
21. Saxena R, Gianniny L, Burtt NP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006;55:2890-2895 (Pubitemid 44923692)
22. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163 (Pubitemid 47219560)
23. Schäfer SA, Tschritter O, Machicao F, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50: 2443-2450 (Pubitemid 350060632)
24. da Silva Xavier G, Loder MK, McDonald A, et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet β-cells. Diabetes 2009;58:894-905.
25. Stančáková A, Kuulasmaa T, Paananen J, et al. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 2009;58:2129-2136
26. Haupt A, Guthoff M, Schäfer SA, et al. The inhibitory effect of recent type 2 diabetes risk loci on insulin secretion is modulated by insulin sensitivity. J Clin Endocrinol Metab 2009;94:1775-1780
27. Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am J Clin Nutr 2009;89:1256-1262
28. Cauchi S, Meyre D, Dina C, et al. Transcription factor TCF7L2 genetic studying the French population. Diabetes 2006;55:2903-2908
29. Melzer D, Murray A, Hurst AJ, et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006;4:34. (Pubitemid 46189714)
30. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009;1:20.
31. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and β-cell function. Best Pract Res Clin Endocrinol Metab 2003;17: 305-322 (Pubitemid 37127434)